CD19 and mantle cell lymphoma: Published clinical data have shown that CAR T cell therapy with CD19 (CD19 CAR T cell therapy) can result in disease remission in 52–82% of patients with r/rNHL [11–16] and even in 93% of patients with mantle-cell lymphoma (MCL) [17].